Social Media

Friday, June 14, 2024

ASCO 2024: Latest Data on Olverembatinib in SDH-Deficient GIST

Ascentage Pharma, a global biopharmaceutical company, recently shared updated clinical data of olverembatinib (HQP1351) at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting. The data showcased promising efficacy and safety of olverembatinib in patients with TKI-resistant succinate dehydrogenase-deficient gastrointestinal stromal tumor (GIST). This marks the third consecutive year that Ascentage’s olverembatinib study has been selected for presentation at ASCO.

Olverembatinib, a third-generation tyrosine kinase inhibitor developed by Ascentage Pharma, has shown significant clinical benefits in SDH-deficient GIST patients. The Phase I study demonstrated a clinical benefit rate of 92.3% and a median progression-free survival of 25.7 months. Olverembatinib is currently approved in China for certain indications in patients with chronic myeloid leukemia, and it is being evaluated for the treatment of SDH-deficient GIST.

Prof. Haibo Qiu from Sun Yat-Sen University Cancer Center presented the latest data on olverembatinib at ASCO, highlighting its impressive clinical benefits and favorable safety profile. Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, expressed excitement over the results, emphasizing the potential breakthrough in addressing the urgent unmet needs of patients with SDH-deficient GIST.

The data presented at ASCO 2024 indicate the promising efficacy of olverembatinib in SDH-deficient GIST and its potential to offer a new treatment option to patients. Ascentage Pharma remains dedicated to advancing its clinical development programs to bring safe and effective therapies to patients worldwide.

In addition to olverembatinib, Ascentage Pharma presented data on other drug candidates, including lisaftoclax and APG-2449, at this year’s ASCO Annual Meeting. The company’s robust pipeline includes novel therapies for cancers, chronic hepatitis B, and age-related diseases, with a focus on inhibiting protein-protein interactions to restore apoptosis.

Ascentage Pharma’s mission is to address unmet clinical needs globally, and the company has established partnerships with leading organizations in the biopharmaceutical industry to advance their research and development efforts. With a strong team and world-class manufacturing capabilities, Ascentage Pharma is committed to accelerating its clinical programs to benefit more patients in need.

For more information about Ascentage Pharma and its innovative drug candidates, visit their official website. Stay tuned for updates on their groundbreaking research and development initiatives to bring new hope to patients facing challenging health conditions.

Source link



Leave a Reply

Your email address will not be published. Required fields are marked *

Featured Franchise Opportunity

Buffalo Wild Wings Go

Food Franchises, Restaurant Franchises

Buffalo Wild Wings

Food Franchises, Restaurant Franchises